公开(公告)号：US20090291947A1

公开(公告)日：2009-11-26

申请号：US12350450

申请日：2009-01-08

Applicant: Bin Shao ,  Jiangchao Yao

Inventor： Bin Shao ,  Jiangchao Yao

IPC: A61K31/535 ,  C07D265/36 ,  A61P3/10

CPC classification number: C07D409/12 ,  C07D207/48 ,  C07D403/12 ,  C07D409/14

Abstract: The present invention relates to Proline Analog Compounds that are ligands for cannabinoid receptors, compositions comprising a Proline Analog Compound and a pharmaceutically-acceptable carrier, methods of making such Proline Analog Compounds, and methods for treating or preventing a Condition comprising administering an effective amount of a Proline Analog Compound to an animal in need thereof.

Abstract translation: 本发明涉及作为大麻素受体配体的脯氨酸类似物化合物，包含脯氨酸类似物化合物和药学上可接受的载体的组合物，制备此类脯氨酸类似物的方法，以及用于治疗或预防病症的方法，包括给予有效量的 脯氨酸类似物化合物给有需要的动物。

公开(公告)号：US07485738B2

公开(公告)日：2009-02-03

申请号：US11857248

申请日：2007-09-18

Applicant: Xinde Xu ,  Lihua Zhang ,  Boqiu Chen ,  Di Zhou ,  Shuangming Ye ,  Chiyu Ding ,  Hongping Lv ,  Bin Shao

Inventor： Xinde Xu ,  Lihua Zhang ,  Boqiu Chen ,  Di Zhou ,  Shuangming Ye ,  Chiyu Ding ,  Hongping Lv ,  Bin Shao

IPC: C07C51/353

CPC classification number: C07C403/24 ,  A23L5/44 ,  A23L33/10 ,  C07C2601/16 ,  C09B61/00 ,  C09B67/0025 ,  C09B67/0096

Abstract: This invention has disclosed a method for preparation of food-grade zeaxanthin through chemical isomerizaton reaction from lutein. The technical issues to be solved in this invention are quite low product yield obtained with existing methods, need of purification treatment process, and inadaptability to industrialized production. The technical schemes of this invention are: a. Mix xanthophyll crystal or its fatty acid ester with food-grade glycol or propylene glycol, for full dissolution under 60-90° C. temperature. Add organic alkali into the mixed liquor acquired from step 1, for isomerization reaction to take place under inertial environment. c. Dilute the reaction solution gained from step b with the mixed solution of deionized water and ethanol, and separate the obtained crystal with conventional separating method. d. Vacuum dries the acquired crystal from step c, to get the zeaxanthin crystal. Glycol or propylene glycol is used in this invention for isomerization reaction under inertial environment after it has fully dissolved raw material under proper temperature. The product yield is reachable to more than 60%, very adaptable to industrialized product, without the need for further purification treatment.

Abstract translation: 本发明公开了通过叶黄素化学异构化反应制备食品级玉米黄质的方法。 本发明要解决的技术问题是用现有方法获得的产品产率相当低，需要净化处理工艺，以及对工业化生产的适应性。 本发明的技术方案是：a。 将叶黄素晶体或其脂肪酸酯与食品级二醇或丙二醇混合，在60-90℃的温度下完全溶解。 将有机碱添加到从步骤1获得的混合液中，以在惯性环境下进行异构化反应。 C。 用去离子水和乙醇的混合溶液稀释从步骤b获得的反应溶液，并用常规分离方法分离得到的晶体。 d。 真空干燥步骤c获得的晶体，得到玉米黄质晶体。 乙二醇或丙二醇在本发明中在适当温度下完全溶解原料之后，在惯性环境下用于异构化反应。 产品产量可达60％以上，非常适用于工业化产品，无需进一步净化处理。

公开(公告)号：US20080194627A9

公开(公告)日：2008-08-14

申请号：US11518448

申请日：2006-09-11

Applicant: Bin Shao ,  R. Goehring ,  Samuel Victory

Inventor： Bin Shao ,  R. Goehring ,  Samuel Victory

IPC: A61K31/4545 ,  A61K31/455 ,  C07D403/02

CPC classification number: C07D213/81 ,  C07D213/82 ,  Y10T436/145555

Abstract: This invention relates aryl substituted pyridines of Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R1—R4 are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

Abstract translation: 本发明涉及式I的芳基取代的吡啶：或其药学上可接受的盐，前药或溶剂化物，其中Ar和R 1 -R 4定义在说明书中。 本发明还涉及式I化合物用于治疗全身和局部缺血后的神经元损伤，用于治疗或预防神经变性疾病如肌萎缩性侧索硬化（ALS）以及治疗，预防或改善的用途 作为抗惊厥剂，作为抗惊厥剂，作为抗躁狂抑制剂，作为局部麻醉剂，作为抗心律失常药物和用于治疗或预防糖尿病性神经病变。

公开(公告)号：US08846929B2

公开(公告)日：2014-09-30

申请号：US12712042

申请日：2010-02-24

Applicant: Kouki Fuchino ,  R. Richard Goehring ,  Bin Shao ,  Yoshiyuki Taoda ,  Naoki Tsuno ,  John William Frank Whitehead ,  Jiangchao Yao

Inventor： Kouki Fuchino ,  R. Richard Goehring ,  Bin Shao ,  Yoshiyuki Taoda ,  Naoki Tsuno ,  John William Frank Whitehead ,  Jiangchao Yao

IPC: C07D295/00

CPC classification number: C07D451/14 ,  A61K31/498 ,  C07D401/04 ,  C07D401/14 ,  C07D451/04 ,  C07D471/08 ,  C07D471/14 ,  C07D487/04 ,  C07D498/08 ,  C07D519/00

Abstract: The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.

Abstract translation: 本发明涉及取代的喹喔啉型哌啶化合物，包含有效量的取代的喹喔啉型哌啶化合物的组合物和治疗或预防诸如疼痛的病症的方法，包括向有需要的动物施用有效量 的取代的喹喔啉型哌啶化合物。

公开(公告)号：US20140187829A1

公开(公告)日：2014-07-03

申请号：US14119149

申请日：2012-05-15

Applicant: Xinde Xu ,  Mingqing Jiao ,  Dong Shao ,  Bin Shao ,  Leiming Yu

Inventor： Xinde Xu ,  Mingqing Jiao ,  Dong Shao ,  Bin Shao ,  Leiming Yu

IPC: C12P23/00

CPC classification number: C12P23/00 ,  A23L5/44 ,  A23L33/155 ,  A23V2002/00 ,  A61K31/015 ,  A23V2250/702

Abstract: The present invention provides a method for producing and purifying β-carotene by Blakeslea trispora fermentation and use thereof. The method comprises the following steps: a) separately inoculating the Blakeslea trispora strains onto a PDA culture medium so as to obtain a spore suspension; b) propagating spores in a seeding tank so as to obtain seeds for fermentation; c) inoculating the seeds for fermentation onto a fermenter and fermenting said seeds; d) adjusting the fermentation liquid to be basic by using an organic or inorganic base, and filtering so as to obtain wet mycelia; e) treating the wet mycelia with a hydrophobic non-polar organic solvent; f) mixing the wet mycelia with an organic solvent of ester and obtaining a concentrated solution by extracting; g) adding a saturated monohydric alcohol into the concentrated solution, and filtering and crystallizing so as to obtain pure ss-carotene. The content of the ss-carotene in the present invention exceeds 96%, and the yield is above 85%.

Abstract translation: 本发明提供了通过三孢a菌发酵及其应用来生产和提纯β-胡萝卜素的方法。 该方法包括以下步骤：a）将单孢菌菌株分别接种到PDA培养基上，得到孢子悬浮液; b）在播种槽中繁殖孢子，以获得用于发酵的种子; c）将种子接种发酵到发酵罐上并发酵所述种子; d）通过使用有机或无机碱调节发酵液为碱性，过滤以获得湿菌丝体; e）用疏水性非极性有机溶剂处理湿菌丝体; f）将湿菌丝体与酯的有机溶剂混合，通过萃取获得浓缩溶液; g）向浓缩溶液中加入饱和一元醇，过滤结晶，得到纯β-胡萝卜素。 本发明中β-胡萝卜素的含量超过96％，收率高于85％。

公开(公告)号：US08765736B2

公开(公告)日：2014-07-01

申请号：US12599608

申请日：2008-09-26

Applicant: Bin Shao ,  Jiangchao Yao

Inventor： Bin Shao ,  Jiangchao Yao

IPC: A01N43/00 ,  A61K31/55 ,  A01N43/42 ,  A61K31/44 ,  A01N43/38 ,  A61K31/40

CPC classification number: C07D211/58 ,  C07D401/04

Abstract: The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1, R2, R3, Z and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula I to treat a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

Abstract translation: 本发明涉及式（I）的氮杂环丁烷基，吡咯烷基，哌啶基和六氢氮杂卟啉化合物及其药学上可接受的盐，前药或溶剂化物，其中R1，R2，R3，Z和q如说明书所述定义。 本发明还涉及使用式I化合物来治疗对阻断钙通道，特别是N型钙通道有响应的病症。 本发明的化合物特别适用于治疗疼痛。

公开(公告)号：US08748495B2

公开(公告)日：2014-06-10

申请号：US13255271

申请日：2010-03-04

Applicant: Xinde Xu ,  Guohua Wei ,  Xuebing Xiang ,  Bin Shao

Inventor： Xinde Xu ,  Guohua Wei ,  Xuebing Xiang ,  Bin Shao

IPC: A61K31/122

CPC classification number: A23L33/105 ,  A23L5/44 ,  A23L33/10 ,  A23V2002/00 ,  A23V2250/211

Abstract: The present invention relates to a method for preparing a carotenoid oil suspension with low viscosity and high fluidity. The method includes the steps of mixing carotenoid crystals with tetrahydrofuran, heating the resulting mixture to a reflux temperature of about 50˜70° C. under stirring, and filtering-the resulting solution to remove fat-soluble fibers. The resulting filtrate is then condensed to dryness, mixed with a ketone solvent, heated to a reflux temperature of about 60˜80° C., and filtered to remove non-soluble phospholipids. The filtrate obtained is condensed to a residue, and absolute alcohol is added to the residue, and then crystallized under stirring at room temperature. The resulting crystals are filtered and dried to-provide carotenoid crystals. The carotenoid crystals are ground and mixed with plant oils to provide a carotenoid oil suspension with low viscosity and high fluidity, which provides easy filling, for example, into capsules.

Abstract translation: 本发明涉及一种制备低粘度和高流动性的类胡萝卜素油悬浮液的方法。 该方法包括将胡萝卜素晶体与四氢呋喃混合的步骤，在搅拌下将所得混合物加热至约50℃至70℃的回流温度，并过滤所得溶液以除去脂溶性纤维。 然后将所得滤液冷凝至干，与酮溶剂混合，加热至约60〜80℃的回流温度，过滤除去不溶性磷脂。 将得到的滤液冷凝成残渣，向残渣中加入无水乙醇，在室温下搅拌结晶。 将所得晶体过滤并干燥以提供类胡萝卜素晶体。 将类胡萝卜素晶体研磨并与植物油混合，以提供低粘度和高流动性的类胡萝卜素油悬浮液，其可以容易地填充到例如胶囊中。

公开(公告)号：US20140005212A1

公开(公告)日：2014-01-02

申请号：US13996082

申请日：2011-12-21

Applicant: Chiyou Ni ,  Minnie Park ,  Bin Shao ,  Laykea Tafesse ,  Jiangchao Yao ,  Mark Youngman ,  Xiaoming Zhou

Inventor： Chiyou Ni ,  Minnie Park ,  Bin Shao ,  Laykea Tafesse ,  Jiangchao Yao ,  Mark Youngman ,  Xiaoming Zhou

IPC: C07D213/75 ,  C07D413/12 ,  C07D401/12 ,  C07D401/14 ,  C07D213/81 ,  C07D213/76

CPC classification number: C07D213/75 ,  C07D213/76 ,  C07D213/81 ,  C07D401/02 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12

Abstract: The invention relates to substituted pyridine compounds of Formula I: (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, R1b, R2a, R2b, R2c, A1, A2, and X are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.

Abstract translation: 本发明涉及式I的取代的吡啶化合物：（I）及其药学上可接受的盐，前药和溶剂化物，其中R1a，R1b，R2a，R2b，R2c，A1，A2和X定义如 规范。 本发明还涉及式I化合物用于治疗对钠通道阻断有反应的病症。 本发明的化合物特别适用于治疗疼痛。

公开(公告)号：US20130076252A1

公开(公告)日：2013-03-28

申请号：US13548624

申请日：2012-07-13

Applicant: Bin Shao ,  Kenji Tomiyoshi

Inventor： Bin Shao ,  Kenji Tomiyoshi

IPC: H05B33/08 ,  G05F1/46

CPC classification number: H05B33/0842 ,  G05F1/46 ,  H05B33/0824

Abstract: The present disclosure proposes a fully integrated accurate LED output current controlling circuit and method, which can be seamlessly combined with true PWM dimming. The current controlling circuit has an auto zero function in the light-emitting diode driver to eliminate offsets caused by the system, process variations, parasitic effects, dimming and so on in an LED driver application, and thus is capable of controlling the LED current with high accuracy. Moreover, the driver of the present disclosure does not require the use of external components such as an external resistor to regulate current accuracy.

Abstract translation: 本公开提出了一种完全集成的准确的LED输出电流控制电路和方法，其可以与真实的PWM调光无缝组合。 电流控制电路在发光二极管驱动器中具有自动调零功能，以消除LED驱动器应用中由系统引起的偏移，工艺变化，寄生效应，调光等，从而能够控制LED电流 高准确率。 此外，本公开的驱动器不需要使用诸如外部电阻器的外部组件来调节电流精度。

公开(公告)号：US20100048626A1

公开(公告)日：2010-02-25

申请号：US12546572

申请日：2009-08-24

Applicant: Bin SHAO ,  R. Richard Goehring ,  Samuel F. Victory ,  Qun Sun

Inventor： Bin SHAO ,  R. Richard Goehring ,  Samuel F. Victory ,  Qun Sun

IPC: A61K31/4545 ,  C07D401/12 ,  C07D213/56 ,  A61K31/4418 ,  A61P25/00 ,  G01N33/00

CPC classification number: C07D213/81 ,  C07D213/82 ,  Y10T436/145555

Abstract: This invention relates aryl substituted pyridines of Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R1-R4 are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

Abstract translation: 本发明涉及式I的芳基取代的吡啶：或其药学上可接受的盐，前药或溶剂化物，其中Ar和R 1 -R 4被置于说明书中。 本发明还涉及式I化合物用于治疗全身和局部缺血后的神经元损伤，用于治疗或预防神经变性疾病如肌萎缩性侧索硬化（ALS）以及治疗，预防或改善的用途 作为抗惊厥剂，作为抗惊厥剂，作为抗躁狂抑制剂，作为局部麻醉剂，作为抗心律失常药物和用于治疗或预防糖尿病性神经病变。